Approaches to the prevention and management of cardiovascular disease (CVD) are often too narrow in scope and initiated too late. While the majority of adolescents are free of CVD, far fewer are free of CVD risk factors, especially lifestyle factors such as poor exercise and dietary habits. Most clinicians are familiar with behavioral and pharmacologic strategies for modifying these and other traditional CVD risk factors such as hypertension, hypercholesterolemia, and diabetes. In this review, we highlight those strategies most applicable to teens and also propose fundamental reframing that recognizes the importance of early choices and life experiences to achieving cardiovascular health. Populationand individual-level approaches that support the establishment of positive health behaviors early in life are the foundation of preserving ideal cardiovascular health and promoting positive cardiovascular outcomes. The Positive Youth Development movement supports a frame shift away from seeing young people as merely the sum of their risk factors and instead as developmentally dynamic youth capable of making healthy choices. Informed by the Positive Youth Development framework, our approach to cardiovascular prevention among adolescents is both broad based and proactive, paying heed as early as possible to social, familial, and developmental factors that underlie health behaviors and employing evidence-based behavioral, pharmacologic, and surgical treatments when needed.
Introduction
The American Heart Association (AHA) introduced the concept of ideal cardiovascular health in 2010 [1••]. The ideal cardiovascular health construct emerged from decades of data showing that adults who reach middle age without traditional cardiovascular disease (CVD) risk factors have remarkably low morbidity and mortality from CVD [2] [3] [4] [5] . The seven factors that comprise ideal cardiovascular health-maintaining a normal body mass index (BMI), adhering to a healthy diet, staying physically active, abstaining from smoking, and having blood pressure, total cholesterol, and fasting blood glucose levels in the normal range without need for pharmacologic treatment-seem obvious to most people familiar with CVD (Table 1) . However, epidemiologic data consistently show that few adults-less than 20 %-reach middle age with five or more of the ideal cardiovascular health metrics [6••]. Children and adolescents have better cardiovascular health than adults, but in the USA, only 50 % of teens have five or more cardiovascular health metrics at the ideal levels; prevalence of individual ideal metrics varies from G1 to 88 % [6••] ( Table 2) . Even in childhood, having all the seven ideal cardiovascular health metrics is extremely rare (less than 1 % of the US population), largely due to unhealthy dietary patterns [7] . The overall narrative is one of the early and progressive losses of cardiovascular health assets [8, 9 •] leading to substantial risk of future CVD outcomes upon reaching young adulthood [10] .
Though concerning, these statistics also highlight the potential for tremendous positive gains at a population level if effective preventive efforts are employed. Improving the cardiovascular health of children is a crucial public health priority that will pay dividends well into the future as young people transition into adulthood. Primordial prevention, which refers to the prevention of risk factor development, is well aligned with the concept of ideal cardiovascular health [11••] . Primary prevention, which refers to the treatment of risk factors in patients who have not yet developed clinical CVD, is also critical. In fact, the AHA recognizes those with risk factors treated to goal as having intermediate cardiovascular health [1••]. There is evidence that primordial and primary prevention strategies at both the individual and population level are likely to be cost-saving, given the high costs of treating established CVD [12] .
Adolescence is a critical time for prevention of CVD. Data from several epidemiologic cohorts confirm that having more ideal cardiovascular health metrics in adolescence [13, 14] and young adulthood [15] is associated with better cardiovascular health later in life. Furthermore, improvement in cardiovascular health metrics during the transition from adolescence to adulthood is associated with more favorable intermediate markers of atherosclerosis. In the Young Finns study, each additional ideal cardiovascular health metric gained in adolescence was associated with improved pulse wave velocity in adulthood [8] , and in the CARDIA study, each additional metric gained in young adulthood was associated with lower odds of coronary artery calcification and lower carotid intima media thickness in middle age [16] .
In this review, we will examine the most recent advances in evidence-based primordial and primary prevention of CVD in adolescents transitioning to young adulthood. We will also explore Positive Youth Development (PYD), a foundational concept in adolescent health promotion that highlights the importance of psychosocial assets and resources in understanding how lifelong preservation of ideal cardiovascular health can actually occur. Beyond prevention of risk factors, true primordial prevention must address the full spectrum of influences that support or erode ideal cardiovascular health throughout the life course.
Treatment
Positive Youth Development: reframing treatment as prevention Establishment and maintenance of healthy behaviors (primordial prevention), including adherence to a healthy dietary pattern, being physically active, and abstaining from tobacco use, are the mainstays of CVD prevention in teens. As such, there has been great interest in understanding the developmental processes and influences that can support the establishment of healthful behaviors from early in life. PYD is a conceptual framework highlighted in Healthy People 2020 that offers important insights in this regard. PYD focuses on each youth's development of personal assets and resources rather than mitigation of vulnerabilities and problems [17] . Typically applied in community-based contexts, PYD programs seek to provide opportunities that will capitalize on a youth's strengths and unique contributions, usually combining skill building, supportive youth-adult relationships, and opportunities to exert influence and serve in leadership capacities. The assets that derive from PYD help youth avoid risk behaviors and promote thriving across multiple domains [18, 19] . Insofar, as poor cardiovascular health behaviors are risk behaviors, proactive strength and asset development through PYD approaches may create a foundation for primordial cardiovascular prevention (Fig. 1) . A growing literature highlights important linkages between PYD and psychosocial well-being during adolescence and cardiovascular health in adulthood. Early life socioeconomic adversity negatively affects young adult cardio-metabolic risk in part through negative effects on psychosocial development related to self-esteem, positive affect, and educational attainment [20•] . Childhood attention regulation, Population-level and community-based interventions in schools, workplaces, and broader communities will be critical in realizing the potential of PYD interventions in primordial CVD prevention. Recent small-scale interventions have begun to apply PYD strategies in promoting cardiovascular health awareness and action among adolescents in school settings, although linkages to specific health behavior outcomes have not yet been characterized [23] . Clinicians primarily involved in direct patient care can contribute meaningfully to these broader efforts by elucidating key issues at the patient and family level and proactively supporting community-based and advocacy efforts to address upstream influences on health decisions and behaviors among youth.
In diabetes or chronic kidney disease due to their low side effect profile and lack of need for laboratory monitoring. A starting dose of amlodipine 2.5 mg daily, titrated up to 5-10 mg daily, has been shown to be effective and safe for long-term use in adolescents [56] . & For teens with diabetes or chronic kidney disease, angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) should be used. Enalapril (starting dose 2.5 mg daily, titrated to a maximum dose of 40 mg daily), lisinopril (starting dose 5 mg daily, titrated to a maximum dose of 40 mg daily), losartan (starting dose 25 mg daily, titrated to a maximum dose of 100 mg daily), and valsartan (starting dose 40 mg daily, titrated to a maximum dose of 160 mg daily) all have excellent data for use in adolescents [56] . Routine measurement of electrolytes and kidney function is required. Pregnancy is contraindicated while using ACE inhibitors or ARBs, and thus, a reliable form of contraception must also be prescribed for sexually active females. The use of either the levonorgestrel-releasing intrauterine device or the etonogestrel implant is recommended, given that they do not lead to increases in blood pressure and do not rely on the teen remembering to take these [57] . Obesity & Pharmacologic treatment of obesity is largely off-label in teens, with the exception of orlistat which is approved for patients aged 12 years and older and the sympathomimetic drugs (such as phentermine) which are approved for patients aged 16 years and older. Weight loss in obese teens is less with orlistat (mean decrease in body mass index of 0.83 kg/ m 2 ) compared to the sympathomimetics (mean decrease in body mass index of 2.20 kg/m 2 with sibutramine, now off the market due to an increase in cardiovascular events in adults) [69] . However, orlistat is recommended as first line, given that less than 1 % of the drug is systemically absorbed and its side effects are limited to the gastrointestinal issues of bloating and diarrhea and malabsorption of fatsoluble vitamins. There is also a concern for abuse of the sympathomimetics with teens. & Metformin has been shown to reduce body mass index on average by 1.38 kg/m 2 in trials of obese adolescents without diabetes [70] and can be considered for adolescents with signs of insulin resistance or risk factors for diabetes.
Cholesterol

Tobacco dependence
& Pharmacologic assistance for smoking cessation with nicotine replacement therapy (NRT), bupropion, or varenicline should be offered to patients aged 18 years and older who desire to quit smoking and should be given in combination with behavioral support [71] . & Concerns exist about the toxicity of nicotine on the developing adolescent brain based on animal models [72] . However, given that longterm exposure to nicotine through tobacco addiction is clearly harmful, NRT may be beneficial to some adolescents with nicotine dependence. NRT is available for patients aged below 18 years with a prescription (in contrast to adults, where it is available over the counter). Dosage should be based on the number of cigarettes smoked per day, with most adolescent smokers started at the 7 mg/patch or 14 mg/patch dose, unless they are very heavy smokers. Nicotine gum or lozenges can also be prescribed for adolescents; the 2 mg strength for each is recommended for this age group. Nicotine nasal spray is not well tolerated by teens and, therefore, not recommended [73] . & Data on the efficacy of NRT in patients younger than 18 years is mixed, with some studies showing abstinence rates of up to 20 % with NRT [74] . However, abstinence rates with NRT are not clearly superior to counseling alone in trials with adolescents and data on long-term abstinence after NRT in teens is discouraging [75] . This may reflect challenges with adherence and/or motivations for smoking beyond nicotine dependence in this age group. & There are very few trials of bupropion or varenicline with adolescents [75, 76••] , and due to concerns about mood dysregulation with their use, off-label use in teens is discouraged.
Surgical treatment
& Bariatric surgery is approved for adolescents with a BMI ≥35 kg/m 2 with serious comorbidities (type II diabetes, moderate to severe sleep apnea, pseudotumor cerebri, or severe non-alcoholic steatohepatitis) or a BMI ≥40 kg/m 2 with less serious comorbidities (hypertension, hyperlipidemia, insulin resistance, or mild sleep apnea) [77] .
& A systematic review of published studies reporting the outcomes of 637 adolescents who underwent bariatric surgery between the years of 1981-2011 found a mean postoperative BMI difference at 1 year of −13.5 kg/m 2 [78] . Similar to studies in adults, Roux-en-Y gastric bypass had the greatest weight loss outcomes and adjustable gastric banding had the least. Data on resolution of comorbidities was poorly documented, but most studies reporting these outcomes found complete resolution of CVD risk factors including hypertension, dyslipidemia, type II diabetes, and sleep apnea at 1 year. & The Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study is the largest prospective cohort study of adolescents undergoing weight loss surgery at five academic referral centers. Teen-LABS investigators reported complication rates of adolescent bariatric surgery of 8-15 % within the first 30 days, including 5 % requiring early reoperation for major surgical complications; no deaths were reported [79] . & Longer-term successes and complications of bariatric surgery in teens beyond 1 year are unknown. Significant concerns exist regarding the effects of bariatric surgery on adolescent physical and emotional development [80] , including risks for vitamin deficiencies, bone loss, and psychiatric conditions such as eating disorders. While some investigators have projected that adolescent bariatric surgery will become costeffective 3 years after the operation due to decreased obesity-related comorbidities [81] , the likelihood of weight regain and need for reoperation over such a long period of follow-up is substantial.
Conclusions
Preservation of ideal cardiovascular health and prevention of cardiovascular disease among adolescents and young adults must begin early and extend across the full scope of young people's lived experiences from the clinic into their neighborhoods, in their schools, and into their homes. While cardiovascular prevention among older adults is typically limited to primary or secondary prevention of cardiovascular outcomes, in adolescence and young adulthood, true primordial prevention is possible. Current data suggest that the vast majority of adolescents have already ceded much of their positive cardiovascular health assets well before adulthood, demanding redoubled efforts to preserve cardiovascular health early on. Positive Youth Development concepts are helpful in shifting the focus of cardiovascular care away from simply addressing risk factors among some to conceiving of what positive cardiovascular development might actually look like for all. CVD prevention must incorporate a deep understanding of the importance of youth developmental trajectories and social determinants of health, along with application of evidence-based behavioral and pharmacological tools when risk factors emerge and primary prevention is needed. Such a coordinated and comprehensive approach will help shift the narrative away from early and progressive loss of cardiovascular health to prolonged preservation of cardiovascular health assets well into adulthood.
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